

America's biopharmaceutical companies stand with everyone affected by the terrible COVID-19 surge in India and patients around the world.

Biopharmaceutical companies are working around the clock to meet the demands of COVID-19 by developing and delivering therapeutics and vaccines. Companies are also providing financial support and in-kind donations to organizations, building capacity with Indian manufacturers, entering into licensing agreements, supporting frontline workers and collaborating with global health authorities to combat this public health crisis.

Recent examples of PhRMA member company contributions to India include:

## AbbVie

The AbbVie Foundation is providing \$1.2 million in grants to disaster relief organizations supporting the COVID-19 surge in India and Brazil. Funding will help secure oxygen equipment, ventilators, PPE, ICU beds and other essential equipment to support patients. The AbbVie Foundation will also match employee donations 2:1 to a select number of nonprofits supporting disaster relief for the COVID-19 surges in India, Brazil and other emerging markets. The Employee Relief Program continues to be available to support our employees in India and across the world who are experiencing financial hardship due to COVID-19.

## Amgen

The Amgen Foundation has approved \$1.25 million to support COVID-19 emergency disaster relief efforts in India and other hard-hit countries with limited health infrastructure and capacity. The Amgen Foundation plans to donate \$500,000 to Direct Relief, \$500,000 to Project Hope, and \$250,000 to the International Medical Corps. Importantly, the Amgen Foundation will also match staff donations to the following charities dollar for dollar: Direct Relief, Project Hope, International Medical Corps, The American India Foundation, CARE and Oxygen For India.

## AstraZeneca

Through AstraZeneca's partnership with COVAX, the company is providing access to the most vulnerable communities in the world, at no profit. In India, for example, which is in the midst of a devastating second wave, most of the vaccines being supplied are manufactured by AstraZeneca's sub-licensing partner, Serum Institute of India. AstraZeneca's vaccine has played a leading role in the COVAX facility, providing 98% of its supply to date.

AstraZeneca also pledged \$1 million in humanitarian aid to support relief activities in India as well as other communities around the world hardest hit by the pandemic. This includes directing \$250,000 to Direct Relief to support their efforts in India, which includes the

distribution of oxygen concentrators, medicines, other supplies and personal protective equipment (PPE) to provide treatment and care for those with COVID-19.

## Bayer

Bayer is donating around EUR 400,000 to the Bayer Foundation India for initiatives in mental support for frontline health care workers, quarantine centers, vaccination efforts and to procure oxygen concentrators to be distributed to public health centers in communities near Bayer sites.

## Boehringer Ingelheim

Through BI Cares Foundation Matching Gifts Program, BI is inviting its U.S. employees to donate to international COVID-19 relief through its NGO partner, Americares. The company will match employee donations dollar for dollar. In addition, the Foundation will be making an initial \$10,000 donation directly to Americares for India COVID-19 relief. BI will continue to monitor the situation and act accordingly.

## Bristol Myers Squibb

The Bristol Myers Squibb Foundation responded urgently with two donations: \$100,000 to the American India Foundation and \$50,000 to Direct Relief. The Foundation and its disaster relief partners will continue to diligently monitor the situation worldwide to provide support as needed.

## Eli Lilly and Company

Eli Lilly and Company (Lilly) is bringing the full force of its scientific and medical expertise to attack the coronavirus pandemic in India and around the world. Lilly is offering donations of baricitinib to the Indian government through Direct Relief while simultaneously working with local Indian pharmaceutical companies to execute royalty-free voluntary licensing agreements to accelerate the manufacturing and distribution of the medicine in India during the pandemic. An initial donation of 400,000 baricitinib tablets is being made immediately

available to the Indian government for eligible hospitalized COVID-19 patients in India and Lilly is working urgently to increase the quantity of donated product multifold over the coming weeks. Working through Direct Relief, Lilly is also donating COVID-19 therapies to low- and lower-middle income countries most heavily impacted by the pandemic.

## EMD Serono

EMD Serono is committed to care for its colleagues, their families and all people affected with urgently needed resources, such as oxygen concentrators. As the current development remains critical, the company is continuously monitoring the situation to support its colleagues in India. EMD Serono will implement the following measures based on the regulations of local authorities in the country: 1) Support vaccination of its employees and family members by private health care facilities; 2) Provide a donation of oxygen concentrators worth approximately 250,000 Euros to help overcome the shortage of oxygen for lung ventilation; and 3) The company in India is working tirelessly supporting colleagues with a 24/7 help line, telephonic doctor consultation for home quarantine, identifying hospitals and oxygen support for critical patients among employees and their families.

## Gilead

Gilead quickly responded to the crisis in India by initiating efforts to rapidly expand availability of Veklury (remdesivir). On April 26, the company announced that it will be providing technical assistance to its seven India-based voluntary licensing partners, supporting the addition of new local manufacturing facilities, and donating API to rapidly scale up production of remdesivir. Remdesivir is approved in India for restricted emergency use for the treatment of suspected or laboratory confirmed COVID-19 in adults and children hospitalized with severe disease. In addition to providing support to its licensees to expand their local manufacturing capacity, Gilead also announced they will donate at least 450,000 vials of Veklury (remdesivir) to the Government of India to help address the immediate needs of Indian patients.

## Johnson & Johnson

Johnson & Johnson's actions are guided by its Credo, which says in part, "...we are responsible to the communities in which we live and work and to the world community." That's why the company is mobilizing global resources to help address the urgent needs of the Indian people. First, Johnson & Johnson is exploring how best to accelerate the delivery of its single-shot, easily transportable COVID-19 vaccine to the people of India through our global supply network, including its manufacturing partnership with Hyderabad-based Biological E. Limited.

Johnson & Johnson has also begun making donations to relief partners, including AmeriCares India, India Red Cross, Seva Sahayog Foundation, and to the hardest-hit areas through local non-governmental organizations. Additionally, Johnson & Johnson has joined the US-India Strategic Partnership Forum to donate 1,000 oxygen concentration devices. The company will continue to expand support and look for ways to support their colleagues so that they don't have to face this crisis alone.

## Merck

Merck, known as MSD outside the United States and Canada, announced that the company has entered into non-exclusive voluntary licensing agreements for molnupiravir with five established Indian generics manufacturers. Molnupiravir is an investigational oral antiviral agent currently being studied in a Phase 3 trial for the treatment of non-hospitalized patients with confirmed COVID-19. Merck is developing molnupiravir in collaboration with Ridgeback Biotherapeutics. Merck has entered into these agreements to accelerate availability of molnupiravir in India and in other low- and middle-income countries (LMICs) following approvals or emergency authorization by local regulatory agencies. The agreements have been signed with Cipla Limited, Dr. Reddy's Laboratories Limited, Emcure Pharmaceuticals Limited, Hetero Labs Limited and Sun Pharmaceutical Industries Limited – five generics manufacturers with World Health Organization (WHO) Pre-Qualified Manufacturing facilities and experience as major suppliers to global and key LMIC procurers. Under the agreements, Merck will provide licenses to these manufacturers to supply molnupiravir to India and more than 100 LMICs. Merck is also in discussions with the Medicines Patent Pool to explore the potential for additional licenses.

Separately, Merck will also donate more than \$5 million worth of oxygen-production equipment, masks, hand sanitizer and financial aid to support relief efforts in India.

## Novartis

Novartis's priorities in India are the health and safety of its associates, and of patients who need the company's medicines. Novartis continues to follow Indian government COVID-19 regulations and guidance, and has been proactive in its approach to ensure the safety of its associates, business continuity, keeping production on track and making medicines available to patients in need. Beyond this, Novartis has also supported the government and local authorities including funding the development of a COVID-19 ward for cancer patients, providing protective equipment to frontline workers and meals to the less privileged. The company is currently evaluating several proposals

including providing important equipment to government hospitals aimed at increasing capacity. For Novartis associates, the company has established an Employee Assistance Program in India including additional leave, counselling, expanded medical coverage as well as medical access via telemedicine.

## **Pfizer**

Pfizer announced that in response to the crisis facing India, it is mobilizing the largest humanitarian relief effort in the company's history to provide urgent and immediate support to patients being treated in public hospitals. Pfizer medicines, identified as part of India's COVID treatment protocol, and valued at more than \$70 million, will be made available immediately. Pfizer will work closely with the government and NGO partners to get the medicines to where they are needed most. This effort has the potential to impact the lives of hundreds of thousands of patients over the next 90 days.

## **Sanofi**

The Sanofi Espoir Foundation is mobilizing to respond to the humanitarian emergency. The Foundation has made a donation to purchase a medical oxygen generator, including a cylinder filling system. The oxygen generator provides a continuous supply to a 250-bed hospital site. The installation's flow rate enables 15 intubated COVID patients to be treated in a resuscitation bay, or 150 patients under oxygen therapy in a standard hospital ward. In addition to responding to emergencies, the equipment will help boost capacity in Indian hospitals.

## **Takeda**

Takeda contributed \$172,000 to the Prime Minister's (PM) Citizen Assistance and Relief in Emergency Situations Fund to support the Government in the fight against COVID-19, with a similar contribution in the pipeline. Additionally, the company recommended credible support organizations to all employees should they wish to personally donate while offering matching programs in some locations. As part of its commitment to the community, the company is currently evaluating setting up makeshift hospitals, oxygen plants in critical states and spreading awareness around vaccination in partnership with the government. Unfortunately, a significant number of Takeda employees and their dependents in India were diagnosed with COVID-19. The company immediately raised awareness among the staff and their families through dedicated internal committees, assisted them in any (pre- or post-) safety measures, ranging from reporting, home isolation procedures, testing assistance, treatment guidance, and, if critical, procuring oxygen concentrators. Moreover, the employees' and dependents' medical insurance policies are extended to include COVID-19 treatment protocols with broader coverage of both hospital and home options. Tie-ups are being finalized with health care providers to provide facilities like home ICU set-up and teleconsultations.